How to buy Telix Pharmaceuticals (TLX) shares in Australia
Learn how to easily invest in Telix Pharmaceuticals shares.
Telix Pharmaceuticals is a biotechnology business based in Australia. Telix Pharmaceuticals shares (TLX) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian dollars. Telix Pharmaceuticals has a trailing 12-month revenue of around $356.9 million. If you're looking to buy shares, check out the steps below.
How to buy shares in Telix Pharmaceuticals
- Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the ASX. Our table can help you choose.
- Open and fund your brokerage account. Complete an application with your personal and financial details, such as your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
- Search for Telix Pharmaceuticals . Find the share by name or ticker symbol: TLX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Telix Pharmaceuticals reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
- Check on your investment. Congratulations, you own a part of Telix Pharmaceuticals . Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.
What's in this guide?
- Telix Pharmaceuticals key stats
- Compare share trading platforms
- Is Telix Pharmaceuticals stock a buy or sell?
- Telix Pharmaceuticals performance over time
- Telix Pharmaceuticals 's financials
- How volatile are Telix Pharmaceuticals shares?
- Does Telix Pharmaceuticals pay a dividend?
- Other common questions
Telix Pharmaceuticals stock price (ASX:TLX)Use our graph to track the performance of TLX stocks over time.
Telix Pharmaceuticals shares at a glance
|52-week range||$5.825 - $12.79|
|50-day moving average||$10.041|
|200-day moving average||$9.8871|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.34|
Compare share trading platforms
Is it a good time to buy Telix Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Telix Pharmaceuticals price performance over time
|1 week (2023-11-24)||5.76%|
|1 month (2023-11-02)||8.90%|
|3 months (2023-09-01)||-8.24%|
|6 months (2023-06-02)||-8.41%|
|1 year (2022-12-02)||33.92%|
|2 years (2021-12-02)||53.17%|
|3 years (2020-12-02)||147.75%|
|5 years (2018-11-30)||1,368.15%|
Is Telix Pharmaceuticals under- or over-valued?
Valuing Telix Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Telix Pharmaceuticals 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Telix Pharmaceuticals 's EBITDA
Telix Pharmaceuticals 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $26.2 million (£0.0 million).
The EBITDA is a measure of a Telix Pharmaceuticals 's overall financial performance and is widely used to measure a its profitability.
Telix Pharmaceuticals financials
|Revenue TTM||$356.9 million|
|Operating margin TTM||14.28%|
|Gross profit TTM||$98.5 million|
|Return on assets TTM||5.18%|
|Return on equity TTM||-52.36%|
|Market capitalisation||$3 billion|
TTM: trailing 12 months
Telix Pharmaceuticals share dividends
We're not expecting Telix Pharmaceuticals to pay a dividend over the next 12 months.
Telix Pharmaceuticals share price volatility
Over the last 12 months, Telix Pharmaceuticals 's shares have ranged in value from as little as $5.825 up to $12.79. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while Telix Pharmaceuticals 's is 2.424. This would suggest that Telix Pharmaceuticals 's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Telix Pharmaceuticals overview
Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials for the treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with Mauna Kea Technologies and Lightpoint Medical to develop advanced image and radio-guided surgical technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
Stocks similar to Telix Pharmaceuticals
Frequently asked questions
More guides on Finder
How to buy OpenAI stock in Australia
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Best performing stocks on the ASX in 2023 (Updated weekly)
Looking for the best performing stocks in Australia? We update this list weekly.
Cryptocurrency ETFs explained: A simple guide for investors (2023)
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
How to buy Gol Linhas Aereas Inteligentes SA ADR (GOL) shares in Australia
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
How to buy Microsoft (MSFT) shares in Australia
Steps to owning and managing Microsoft shares from in Australia.
A beginner’s guide to Lego investing
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
The cheapest stock brokers in Australia (Dec 2023)
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
What is the money market?
Learn about the money market and everyday consumer money market products.
Is investing in crowdfunding a safe investment?
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
The best trading platforms in Australia for 2023
Follow these tips to find the best share trading platform for you.
Ask an Expert